Ergonomic Training With or Without Structured Exercise in Oil Industry Workers With Chronic Musculoskeletal Pain

November 11, 2026 updated by: Doç.Dr.Ömer Şevgin, Uskudar University

Effect of Structured Exercise Added to Ergonomic Training on Pain, Pain-Related Disability and Quality of Life in Oil Industry Workers With Chronic Musculoskeletal Disorders: A Randomized Controlled Trial

This randomized controlled trial will investigate whether a 12-week structured exercise program added to ergonomic training reduces pain and pain-related disability and improves quality of life more than ergonomic training alone in oil industry workers with chronic musculoskeletal pain. Forty workers aged 25-50 years with musculoskeletal pain lasting at least 3 months will be randomly assigned to either ergonomic training plus exercise or ergonomic training only. Both groups will receive two 45-minute ergonomic training sessions specific to oil-field work (weeks 1 and 6) and a printed brochure. The exercise group will additionally perform a phased neuromuscular and resistance exercise program 3 days per week for 12 weeks, partly supervised at the worksite and partly home/worksite-based. Pain intensity (visual analogue scale), pain-related disability (Pain Disability Index), quality of life (SF-12), regional musculoskeletal symptoms (Extended Nordic Musculoskeletal Questionnaire) and sleep quality (Pittsburgh Sleep Quality Index) will be assessed by an assessor blinded to group allocation at baseline and after 12 weeks.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Background: Work-related musculoskeletal disorders are a leading cause of lost productivity and disability. Oil and gas installations combine heavy lifting, repetitive work, awkward postures, vibrating tools, prolonged standing and shift work; musculoskeletal symptom prevalence of 71-89% has been reported in this workforce. Multicomponent workplace programs combining exercise, ergonomics and education provide the most consistent benefit for pain and function, and ergonomic-educational interventions alone have reduced symptoms in oil and gas workers; however, no randomized controlled trial has evaluated the added value of exercise in this population.

Design: Prospective, assessor-blinded, two-arm, parallel-group, 1:1 randomized controlled trial conducted at a single oil industry facility. The study will be reported according to CONSORT and TIDieR. Participants will be randomized using a computer-generated list with variable block sizes (4 and 6); allocation will be concealed in sequentially numbered, opaque, sealed envelopes prepared by an investigator not involved in treatment or assessment.

Interventions: Both groups receive ergonomic training specific to oil-field work: two 45-minute face-to-face group sessions (8-12 workers) at weeks 1 and 6 covering musculoskeletal risk factors, NIOSH lifting principles, valve/flange and overhead work, hand-arm and whole-body vibration, prolonged standing and grated floors, control-room/office ergonomics, shift work and sleep hygiene, and a 5-minute micro-break routine, plus a printed brochure and micro-break card, with weekly reminder messages for 12 weeks. The exercise group additionally performs a 12-week structured program, 3 non-consecutive days per week, 45 minutes per session (36 sessions): weeks 1-2 fully supervised at the facility in groups of 4-6, weeks 3-12 one supervised and two home/worksite-based sessions per week supported by an illustrated brochure and guided video. Each session comprises warm-up and mobility (6 min), neuromuscular stabilization (12 min), resistance strengthening with elastic bands and light loads (14 min), job-specific functional exercise such as box lifting and carrying (6 min) and stretching (7 min). The program progresses through three phases (motor control and activation, weeks 1-4; endurance and strength, weeks 5-8; job-specific functional loading, weeks 9-12) with intensity targeted at Borg CR-10 4-6 and load progression by the 2-for-2 rule. The control group receives weekly ergonomic reminder messages and a telephone call every 2 weeks to equalize contact; the exercise program is offered to the control group after final assessment.

Outcomes: Assessments at baseline (T0) and at the end of the 12-week intervention (T1) by a physiotherapist blinded to group allocation. Primary outcome: pain intensity on a 0-10 cm visual analogue scale. Secondary outcomes: Pain Disability Index (0-70), SF-12 physical and mental component summaries, regional symptom prevalence on the Extended Nordic Musculoskeletal Questionnaire, and sleep quality on the Pittsburgh Sleep Quality Index (exploratory). Process measures: session adherence, Borg CR-10 and adverse events.

Sample size: A priori power analysis (G*Power 3.1; repeated-measures ANOVA, within-between interaction; f = 0.25, alpha = 0.05, power = 0.80, 2 groups, 2 measurements, correlation 0.50) indicated 34 participants; allowing for 15-20% attrition, 40 participants (20 per group) will be enrolled.

Analysis: Intention-to-treat with multiple imputation; per-protocol (adherence ≥70%) as sensitivity analysis. Primary outcome analyzed with 2 × 2 mixed-design repeated-measures ANOVA (group × time interaction) or ANCOVA on the week-12 score adjusted for baseline. Secondary continuous outcomes analyzed in the same way; Benjamini-Hochberg correction for secondary outcomes. Dichotomous Nordic data analyzed with McNemar and chi-square/Fisher tests. Effect sizes (partial eta squared, Cohen d) with 95% CIs, proportion exceeding the minimal clinically important difference and number needed to treat will be reported. Significance p < 0.05.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 25-50 years
  • Employed in the oil industry for at least 5 years
  • Musculoskeletal pain lasting at least 3 months, with symptoms in at least one body region in the last 12 months and the last 7 days on the Nordic Musculoskeletal Questionnaire
  • Pain intensity ≥3/10 on the visual analogue scale
  • Literate and able to communicate
  • Willing to participate and signing the informed consent form

Exclusion Criteria:

  • Spinal or extremity surgery or trauma within the last 6 months
  • Inflammatory rheumatic disease, radicular neurological signs (motor or reflex loss) or history of malignancy
  • Uncontrolled cardiovascular, pulmonary or neurological disease precluding exercise
  • Pregnancy
  • Physiotherapy/rehabilitation within the last 3 months or regular structured exercise ≥150 minutes per week
  • Planned job change or relocation during the study period

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ergonomic training + structured exercise

Oil-field-specific ergonomic training (two 45-min sessions at weeks 1 and 6, brochure, weekly reminders) plus a 12-week phased neuromuscular and resistance exercise program, 3 days/week, 45 min/session, partly supervised at the worksite.

12 weeks, 3 non-consecutive days/week, 45 min/session (36 sessions). Weeks 1-2 fully supervised by a physiotherapist at the facility (groups of 4-6); weeks 3-12 one supervised + two home/worksite-based sessions per week with illustrated brochure and guided video. Three phases: motor control/activation (weeks 1-4, body weight and light bands), endurance/strength (weeks 5-8, medium bands, 5-8 kg), job-specific functional loading (weeks 9-12, heavy bands, 8-12 kg). Intensity Borg CR-10 4-6; progression by 2-for-2 rule; pain rule ≤3/10 during exercise returning to baseline within 24 h.

Active Comparator: Ergonomic training only (active control)

The same oil-field-specific ergonomic training (two 45-min sessions at weeks 1 and 6, brochure, weekly reminders) and a telephone call every 2 weeks for contact equalization; no exercise program during the study. The exercise program is offered after final assessment.

12 weeks, 3 non-consecutive days/week, 45 min/session (36 sessions). Weeks 1-2 fully supervised by a physiotherapist at the facility (groups of 4-6); weeks 3-12 one supervised + two home/worksite-based sessions per week with illustrated brochure and guided video. Three phases: motor control/activation (weeks 1-4, body weight and light bands), endurance/strength (weeks 5-8, medium bands, 5-8 kg), job-specific functional loading (weeks 9-12, heavy bands, 8-12 kg). Intensity Borg CR-10 4-6; progression by 2-for-2 rule; pain rule ≤3/10 during exercise returning to baseline within 24 h.

Two 45-minute face-to-face group sessions (8-12 workers) at weeks 1 and 6 delivered by a physiotherapist (short presentation, practical demonstration and teach-back, discussion). Content: oil-field musculoskeletal risk factors; NIOSH lifting principles; valve/flange and overhead work; vibrating tools and hand-arm vibration; prolonged standing, grated floors and stairs; vehicle/cabin and whole-body vibration; control-room/office ergonomics; shift schedules and sleep hygiene; 5-minute micro-break routine. Printed brochure and micro-break card; weekly reminder messages for 12 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in pain intensity (Visual Analogue Scale)
Time Frame: Baseline, Week 12

Average pain over the past week marked on a 10 cm horizontal line (0 = no pain, 10 = worst imaginable pain), measured in cm. Lower scores indicate less pain. Minimal clinically important difference ≥2 cm or ≥30%.

Baseline, Week 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in pain-related disability (Pain Disability Index)
Time Frame: Baseline, Week 12

7 items (family/home responsibilities, recreation, social activity, occupation, sexual behavior, self-care, life-support activity) each rated 0-10; total 0-70, higher scores indicate greater disability. Turkish version validated.

Baseline, Week 12
Change in health-related quality of life (SF-12)
Time Frame: Baseline, Week 12

Physical Component Summary (PCS) and Mental Component Summary (MCS) scores, each 0-100; higher scores indicate better quality of life. Turkish version validated.

Baseline, Week 12
Change in regional musculoskeletal symptom prevalence (Extended Nordic Musculoskeletal Questionnaire)
Time Frame: Baseline, Week 12

Presence of symptoms (yes/no) in the last 7 days and last 12 months and activity limitation in nine body regions (neck, shoulders, upper back, lower back, elbows, wrists/hands, hips/thighs, knees, ankles/feet). Turkish version validated.

Baseline, Week 12
Change in sleep quality (Pittsburgh Sleep Quality Index) - exploratory
Time Frame: Baseline, Week 12

Seven component scores (0-3) summed to a global score 0-21; scores >5 indicate poor sleep quality. Turkish version validated.

Baseline, Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Sedat Kartal, Üsküdar University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 15, 2026

Primary Completion (Estimated)

May 20, 2027

Study Completion (Estimated)

May 20, 2027

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • Uskudar32

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

De-identified individual participant data may be made available from the principal investigator upon reasonable request after publication of the main results.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.